Tricida, Inc. (TCDA) Financial Analysis & Valuation | Quarter Chart
Tricida, Inc. (TCDA)
TCDAPrice: $0.11
Fair Value: 🔒
🔒score
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing aci... more
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercializat... more
Description
Shares
| Market Cap | $5.95M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Gerrit Klaerner |
| IPO Date | 2018-06-28 | CAGR | — |
| Employees | 57 | Website | www.tricida.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | 0.55% | Total Yield | 0.55% |
TCDA chart loading...
Fundamentals
Technicals
| Enterprise Value | $798.26M | P/E Ratio | — |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 24.78 |
| P/CF Ratio | -0.04 | P/FCF Ratio | -0.04 |
| EPS | $-5.29 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -3.56% | ROA | -1.15% |
| ROCE | -1.14% | Current Ratio | 4.94 |
| Quick Ratio | 4.94 | Cash Ratio | 0.72 |
| Debt/Equity | 649.28 | Interest Coverage | -9.03 |
| Altman Z Score | -16.65 | Piotroski Score | 1 |